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Autologous stem cell transplantation (ASCT) after high-dose melphalan conditioning is considered a standard
of care procedure for patients with multiple myeloma (MM). Current formulations of melphalan (eg, Alkeran
for Injection [melphalan hydrochloride]; GlaxoSmithKline, Research Triangle Park, NC, USA) have marginal
solubility and limited chemical stability upon reconstitution. Alkeran requires the use of propylene glycol as a
co-solvent, which itself has been reported to cause such complications as metabolic/renal dysfunction and
arrhythmias. EVOMELA (propylene glycol-free melphalan HCl; Spectrum Pharmaceuticals, Inc., Irvine, CA,
USA) is a new i.v. melphalan formulation that incorporates Captisol (Ligand Pharmaceuticals, Inc., La Jolla, CA,
USA), a specially modiﬁed cyclodextrin that improves the solubility and stability of melphalan and eliminates
the need for propylene glycol. This new formulation has been shown to be bioequivalent to Alkeran. EVO-
MELA (200 mg/m2) was administered as 2 doses of 100 mg/m2 each in a phase IIb, open-label, multicenter
study to conﬁrm its safety and efﬁcacy as a high-dose conditioning regimen for patients with MM undergoing
ASCT. At 5 centers, 61 patients (26 women) with a median age of 62 years (range, 32-73) were enrolled. All
patients achieved myeloablation with a median time of 5 days post-ASCT, and all successfully achieved
neutrophil and platelet engraftment with median times of 12 days post-ASCT and 13 days post-ASCT,
respectively; treatment-related mortality on day 100 was 0%. Overall response rate (according to indepen-
dent, blinded review) was high (100%), with an overall complete response rate of 21% (13% stringent complete
response; 8% complete response) and overall partial response rate of 79% (61% very good partial response;
18% partial response). The incidence of grade 3 mucositis and stomatitis was low (10% and 5%, respectively)
with no grade 4 mucositis or stomatitis reported (graded according to National Cancer Institute Common
Terminology Criteria for Adverse Events). Based on investigators’ assessment of mucositis using the World
Health Organization (WHO) oral toxicity scale, 75% of patients had a shift in mucositis score fromWHO grade
0 at baseline to a higher grade on study, of which 13% of patients reported WHO grade 3 as the worst post-
treatment mucositis over the course of the study; there were no reports of WHO grade 4 mucositis during the
study. This study conﬁrms the efﬁcacy and acceptable safety proﬁle of EVOMELA, a new propylene glycol-free
melphalan formulation, as a high-dose conditioning regimen for ASCT in patients with MM.
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Myeloablative conditioning with high-dose chemo-
therapy followed by autologous stem cell transplantation
(ASCT) is considered to be the standard of care treatment for
P. Hari et al. / Biol Blood Marrow Transplant 21 (2015) 2100e2105 2101symptomatic, transplant-eligible patients with multiple
myeloma (MM) [1-3]. Themost commonly used conditioning
regimen in this setting is i.v. administration of high-dose
melphalan [4-6]. Multiple studies have also conﬁrmed
the efﬁcacy of melphalan over other myeloablative therapies
[7-10]. Conventional melphalan formulations (eg, Alkeran;
GlaxoSmithKline, Research Triangle Park, NC, USA) have
marginal solubility, limited chemical stability after recon-
stitution (necessitating completed administration within 1
hour), and require the use of propylene glycol as a co-solvent
[11]. Propylene glycol can potentially contribute to an array
of side effects, including metabolic/renal dysfunction
and arrhythmias [12]. Thus, conventional melphalan
formulations, when administered at the high doses used for
myeloablative conditioning, can put patients at risk of these
potential propylene glycoleassociated toxicities.
Propylene glycol-free melphalan hydrochloride
(EVOMELA; Spectrum Pharmaceuticals, Inc., Irvine, CA, USA)
is a new formulation of melphalan that incorporates Captisol
(Ligand Pharmaceuticals, Inc., La Jolla, CA, USA), a specially
modiﬁed cyclodextrin that improves the solubility and
stability of melphalan [13,14]. This new formulation elimi-
nates the risk of propylene glycol toxicities by using the
Captisol technology used in the formulation of 6 other US
Food and Drug Administrationeapproved human parenteral
drugs (Vfend, Nexterone, Geodon, Abilify, Kyprolis, and
Noxaﬁl) [15-20].
The objective of this study was to conﬁrm the safety and
efﬁcacy of high-dose EVOMELA as a myeloablative condi-
tioning regimen in patients with MM undergoing ASCT.
Propylene glycol-free melphalan HCl has been previously
shown to be bioequivalent to Alkeran in a phase IIa study [14].
METHODS
Patients and Procedures
This phase IIb, open-label, nonrandomized study was conducted at 5
centers in the United States. The primary aim was to conﬁrm the safety and
efﬁcacy of high-dose EVOMELA as a myeloablative conditioning regimen in
patients who had symptomatic MM and qualiﬁed for ASCT. Patients enrolled
in the study received 200 mg/m2 of i.v. melphalan as 2 doses of EVOMELA
(100 mg/m2 each, infusion time of approximately 30 minutes) on days 3
and 2 followed by a day of rest before ASCT was performed on day
0 (Figure 1). The decision to dose melphalan over 2 days was based on the
regimen used in the previously conducted phase IIa study in which pro-
pylene glycol-freemelphalan HCl was shown to be bioequivalent to Alkeran;
prior prospective studies have used the 2-day dosing regimen and author-
ities in the ﬁeld consider both dosing regimens to be equivalent [14,21,22].
Key inclusion criteria included patients with symptomatic MM who
had adequate cardiac, hepatic, renal, and pulmonary function; an Eastern
Cooperative Oncology Group (ECOG) performance status  2; and an
adequate autologous stem cell collection available (2  106 CD34þ
cells/kg). Treatment-related mortality (TRM), adverse events, overall
response rate (ORR), myeloablation, neutrophil engraftment, and plateletFigure 1. Study schema. Patients enrolled in the study received 200mg/m2 of i.v.
melphalan as 2 doses of EVOMELA (100mg/m2 each) ondays3 and2 followed
by a day of rest before ASCTwas performed on day 0. Patients were evaluated for
safety and response through day þ100. CE indicates Captisol-enabled.engraftment were assessed by site investigators as deﬁned below. MM
response rates were initially assessed by the site investigator using the In-
ternational Myeloma Working Group (IMWG) uniform response criteria for
evaluating MM response and were also adjudicated by an independent,
blinded reviewer to ensure consistency across sites.
Myeloablation, neutrophil engraftment, and platelet engraftment were
assessed from daily complete blood counts with differentials conducted
until the time of neutrophil and platelet engraftment. Bone marrow aspi-
rates/biopsies were obtained before study treatment and on day þ100 after
ASCT to further assess disease status. Safety was assessed according to
National Cancer Institute Common Terminology Criteria for Adverse Events
(NCI CTCAE) version 4.03. Mucositis was also assessed using the World
Health Organization (WHO) oral toxicity scale. Agents to treat symptoms of
mucositis (oral narcotics, oral mouthwashes, nondrug cryotherapy, etc.)
were allowed during the study as per institutional protocols.
All patients were informed of the investigational nature of the study; all
signed and were given a copy of written informed consent in accordance
with institutional and federal guidelines. This study was approved by the
institutional review board at each participating site and was registered on
ClinicalTrials.gov (identiﬁcation number: NCT01660633).
Statistical Analyses
MM response rates according to each category of response (stringent
complete response [sCR], complete response [CR], very good partial
response [VGPR], partial response [PR], stable disease, and progressive
disease) were summarized by the proportion of patients meeting each cri-
terion along with Clopper-Pearson 95% conﬁdence intervals (CI). The
Kaplan-Meier methodology was used to summarize time-to-event variables
(time tomyeloablation, time to neutrophil engraftment, and time to platelet
engraftment) along with 95% CIs. The rates of myeloablation, engraftment
(neutrophil and platelets), and nonengraftment in the study population
were determined using the deﬁnitions below and were summarized by the
proportions of patients meeting each criterion.
Adverse event coding was performed using the Medical Dictionary for
Regulatory Activities version 13.1, and the severity of the toxicities was
graded according to NCI CTCAE version 4.03 whenever possible. Adverse
events were summarized by severity and by causality (related and not
related to study treatment) as assessed by the investigators. Clinically
relevant laboratory abnormalities (ie, those that met grade 3 or 4 criteria
according to NCI CTCAE) were summarized. The incidence of oral mucositis
was also summarized byWHO grade. Time from the start of the ﬁrst dose of
study medication to peak oral mucositis score was calculated and was
summarized using Kaplan-Meier estimates.
Deﬁnitions
TRM was deﬁned as death without relapse or progression during
the ﬁrst 100 days after ASCT. ORR was deﬁned as greater than or equal to a
PR by IMWG criteria on day þ100 after ASCT. Neutrophil engraftment was
deﬁned as an absolute neutrophil count > .5  109/L for 3 consecutive daily
assessments. Platelet engraftment was deﬁned as an untransfused platelet
measurement > 20,000/mm3 for 3 consecutive daily assessments. Serious
adverse events (SAEs) were deﬁned as adverse events that resulted in death,
were life-threatening, required hospitalization, resulted in persistent or
signiﬁcant disability/incapacity, resulted in a congenital anomaly/birth
defect, or were considered serious based on medical judgment. Treatment-
emergent adverse events (TEAE) were deﬁned as adverse events that
occurred or worsened on or after ﬁrst study treatment up through 30 days
after last study treatment and/or any treatment-related adverse events
regardless of the onset date. High-risk cytogenetics were deﬁned as t(4;14),
t(14;16), t(14;20), del17p, hypodiploidy, or chromosome 1 abnormalities.
RESULTS
Study Population
A total of 76 patients was screened, and 61 patients were
enrolled. The study population consisted of 35 men (57%)
and 26 women (43%) with a median patient age of 62 years
(range, 32 to 73). Most patients (80%) were white, and 18% of
patients were African American. Most patients (59%) had an
ECOG performance status of 0. Cytogenetics were classiﬁed
as high risk in 15% of patients and standard risk in 48% of
patients; 36% of patients had missing cytogenetic informa-
tion. Five patients (8%) had relapsed disease, and 56 patients
(92%) were newly diagnosed MM receiving upfront ASCT.
Overall, 53 patients (87%) had 1 prior therapy, 5 patients (8%)
had 2 prior therapies, and 3 patients (5%) had 3 or more prior
Table 2
Summary of MM Response (N ¼ 61)
Time Point MM Response Assessment Value
Independent Reviewer
Assessment
Response at day þ100 after
ASCT
Overall response (sCR, CR,
VGPR, or PR)
61 (100%)
sCR 8 (13%)
CR 5 (8%)
VGPR 37 (61%)
PR 11 (18%)
Stable disease 0 (0%)
Progressive disease 0 (0%)
Investigator Assessment
Response at day þ100 after
ASCT
Overall response (sCR, CR,
VGPR, or PR)
58 (95%)
sCR 10 (16%)
CR 9 (15%)
VGPR 26 (43%)
PR 13 (21%)
Stable disease 2 (3%)
Progressive disease 1 (2%)
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Based on the site investigator’s response assessment, pre-
treatment (before ASCT) disease status greater than or equal
to PR was 79%. On independent reviewer’s response assess-
ment, pretreatment (before ASCT) disease status greater
than or equal to PR was 82%. Table 1 summarizes patient
characteristics.
Efﬁcacy Results
Efﬁcacy was determined based on clinical response (MM
responses at day þ100 using the IMWG uniform response
criteria) and by determining the rates and timing of mye-
loablation and engraftments. Clinical response assessments
from both the site investigator and blinded independent
reviewer are presented and discussed.
Clinical response
All patients were assessable for response. Based on the
site investigator’s assessments after EVOMELA and ASCT at
day þ100, ORR was 95% (Table 2, Figure 2). The CR rate wasTable 1
Patient Characteristics (N ¼ 61)
Characteristic Value
Median age, yr (range) 62 (32-73)
Gender
Male 35 (57%)
Female 26 (43%)
Race
White 49 (80%)
Black/African American 11 (18%)
Other 1 (2%)
International staging system stage at diagnosis*
I 28 (47%)
II 16 (27%)
III 15 (25%)
ECOG performance score at transplant
0 36 (59%)
1 23 (38%)
2 2 (3%)
Cytogenetics
High risky 9 (15%)
Standard risk 29 (48%)
Missing 23 (37%)
Prior lines of treatmentz
1 53 (87%)
2 5 (8%)
3 3 (5%)
Relapsed disease 5 (8%)
Prior ASCT 5 (8%)
Pretreatment (before ASCT) response (independent
reviewer assessment)
Overall response (sCR, CR, VGPR, or PR) 50 (82%)
sCR 0 (0%)
CR 3 (5%)
VGPR 27 (44%)
PR 20 (33%)
Stable disease 8 (13%)
Progressive disease 3 (5%)
Pretreatment (before ASCT) response (investigator
assessment)
Overall response (sCR, CR, VGPR, or PR) 48 (79%)
sCR 0 (0%)
CR 6 (10%)
VGPR 22 (36%)
PR 20 (33%)
Stable disease 8 (13%)
Progressive disease 5 (8%)
* A total of 59 patients had International Staging System stage available.
y Deﬁned as t(4;14), t(14;16), t(14;20), del17p, hypodiploidy, or chro-
mosome 1 abnormalities.
z Induction therapy before ASCT included as a prior line of treatment.31%, with 16% sCR and 15% CR; the PR rate was 64%, with 43%
VGPR and 21% PR by day þ100. Based on the independent
reviewer’s response assessment following EVOMELA and
ASCT at day þ100, the ORR was 100% (Table 2, Figure 2). The
CR rate was 21%, with 13% sCR and 8% CR; the PR rate was
79%, with 61% VGPR and 18% PR by dayþ100. In addition, the
5 patients in this study who had relapsed after a prior ASCT
were shown to achieve a response to subsequent treatment
with EVOMELAwith 1 sCR, 2 CRs, 1 VGPR, and 1 PR based on
the independent reviewer assessment.
Myeloablation, neutrophil engraftment, and platelet
engraftment
All patients achieved myeloablation with a median time
of 5 days post-ASCT (range, 1 to 6). All patients successfully
achieved neutrophil and platelet engraftment with median
times of 12 days post-ASCT (range,10 to 16) and 13 days post-
ASCT (range, 10 to 28), respectively.
Safety Results
All 61 patients in the study received 2 doses of EVOMELA
at 100 mg/m2 each on days 3 and 2 for a total dose of 200
mg/m2. The duration of infusion of the melphalan doses
varied between 24 and 48 minutes, with a mean infusion
time of 32.8 minutes. No TEAEs led to discontinuation from
the study.18% 21%
61%
43%
8%
15%
13%
16%
0%
25%
50%
75%
100%
Post-CE-Melphalan /ASCT (Day +100) (N = 61)
(Independent Reviewer Assessment)
Post-CE-Melphalan /ASCT (Day +100) (N = 61)
(Invesgator Assessment)
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Figure 2. MM response rates were assessed by an independent reviewer (left)
and by the site investigator (right) using the IMWG uniform response criteria
for evaluating MM response.
Table 4
Summary of Nonhematologic TEAEs Experienced by 25% of Patients
(N ¼ 61)
Adverse Event No. of Patients (%)
Diarrhea 57 (93)
Nausea 55 (90)
Fatigue 47 (77)
Hypokalemia 45 (74)
Vomiting 39 (64)
Hypophosphatemia 30 (49)
Decreased appetite 30 (49)
Pyrexia 29 (48)
Constipation 29 (48)
Mucosal inﬂammation 23 (38)
Dizziness 23 (38)
Peripheral edema 20 (33)
Stomatitis 17 (28)
Abdominal pain 17 (28)
Dysgeusia 17 (28)
Dyspepsia 16 (26)
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There were no deaths on study; thus, TRM was 0%.
Hematologic TEAEs
All patients (100%) had at least 1 grade 4 hematologic
TEAE indicative of myeloablation. Grades 3 to 4 hematologic
TEAEs are presented in Table 3.
Nonhematologic TEAEs
All patients (100%) had at least 1 nonhematologic TEAE.
Nonhematologic TEAEs that were reported in 25% of
patients are presented in Table 4. Nonhematologic TEAEs
were reported as grade 3 in 69% of patients and grade 4 in
10% of patients. Grade 3 nonhematologic TEAEs reported in
5% of patients were hypophosphatemia (41%), hypokalemia
(26%), mucosal inﬂammation (10%), hyperglycemia (8%),
stomatitis (5%), hypocalcemia (5%), and hypertension (5%).
Grade 4 nonhematologic TEAEs included hypophosphatemia
(4 patients), sepsis (2 patients), hematochezia (1 patient),
and hypokalemia (1 patient). Notably, the incidence of grade
3 mucositis and grade 3 stomatitis was low (10% and 5%,
respectively), and no grade 4 mucositis or grade 4 stomatitis
was reported. All grades 3 and 4 TEAEs resolved over the
course of the study.
Serious adverse events
Twelve patients (20%) experienced treatment-emergent
SAEs while on study, and all SAEs resolved. Ten of the
treatment-emergent SAEs were considered at least possibly
related to study treatment, and the remaining 8 were
considered unlikely or not related to study treatment.
Treatment-emergent SAEs included pyrexia (5 patients, 8%);
febrile neutropenia, hematochezia, and acute renal failure
(2 patients each, 3%); and atrial ﬁbrillation, cellulitis,
dehydration, mucosal inﬂammation, oral pain, presyncope,
and staphylococcal infection (1 patient each, 2%). Most
treatment-emergent SAEs were grade 3 and included 2
events each of pyrexia and acute renal failure and 1 event
each of mucosal inﬂammation, hematochezia, oral pain,
febrile neutropenia, cellulitis, staphylococcal infection, atrial
ﬁbrillation, dehydration, and presyncope. One treatment-
emergent SAE (hematochezia) was grade 4. These
treatment-emergent SAEs are commonly reported events
noted during myeloablative therapy [23-25].
Oral mucositis
Based on investigators’ assessment using the WHO
oral toxicity scale, 46 patients (75%) had a shift in mucositisTable 3
Summary of Hematologic TEAEs by Worst Grade
Adverse Event Grade 3 Grade 4 All*
All hematologic adverse eventsy 61 (100) 61 (100) 61 (100)
Neutropenia/neutrophil count
decreased
3 (5) 58 (95) 61 (100)
Leukopenia/WBC count decreased 1 (2) 60 (98) 61 (100)
Lymphopenia/lymphocyte count
decreased
0 (0) 60 (98) 60 (98)
Thrombocytopenia/platelet count
decreased
0 (0) 60 (98) 60 (98)
Anemia 31 (51) 0 (0) 40 (66)
Febrile neutropenia 17 (28) 0 (0) 25 (41)
Values are number of cases with percents in parentheses.
* All adverse events indicative of myeloablation regardless of worst
toxicity.
y Patients were counted only once across the combined preferred terms
by worst toxicity.score from grade 0 at baseline to a higher grade on study,
of which 8 patients (13%) reported grade 3 as the worst post-
treatment mucositis over the course of the study. There were
no reports of grade 4 mucositis during the study (Table 5).
Adverse events of special interest
Adverse events of special interest included atrial ﬁbrilla-
tion and acute renal failure. Three patients (5%) had TEAEs of
atrial ﬁbrillation: 2 were grade 2 and 1 was grade 3. The
grade 3 atrial ﬁbrillation was a treatment-emergent SAE that
occurred in a patient with a history of hypercholesterolemia
and hypertension that resolved 8 days after the last dose of
study medication. For the 2 patients with grade 2 atrial
ﬁbrillation, 1 patient had a history of atrial ﬁbrillation,
hyperlipidemia, and hypertension, and the other patient had
a history of hypercholesterolemia, hypertension, and coro-
nary artery disease. Three patients (5%) had TEAEs of acute
renal failure that resolved on follow-up. All events of acute
renal failure were considered not to be related to the study
medication. Two acute renal failure events were grade 3
treatment-emergent SAEs, and 1 event was a grade 2 TEAE.
DISCUSSION
A previously conducted phase IIa pharmacokinetic
crossover study (n ¼ 24) showed the efﬁcacy of propylene
glycol-free melphalan HCl given as a high-dose conditioning
regimen to patients with MM undergoing ASCT, with all
patients achieving myeloablation and subsequent hemato-
logic engraftment; the observed safety proﬁle was consistent
with that already established for conventional melphalan
formulations [14]. Additionally, this study demonstrated the
bioequivalence of propylene glycol-free melphalan HCl
to Alkeran for Injection with mean plasma concentration
proﬁles that were nearly superimposable for the 2melphalan
formulations [14]. Geometric mean ratios from a non-
compartmental analysis demonstrated model-estimated
Cmax, AUC0-N, and AUC0-t values of 112.0%, 110.9%, and
110.8%, respectively, with associated 90% CIs within 80.0% to
125.0%.
A phase IIa bioequivalence study directly compared
Alkeran with propylene glycol-free melphalan HCl and was
designed as a crossover study that administered 1 or the
other product on the ﬁrst day followed by the alternate
product on the second day [14]. Therefore, the dosing in the
phase IIa study had to be 100 mg/m2 over 2 days, and the
Table 5
Shift in Mucositis Results
Baseline Mucositis Result Worst Postbaseline Mucositis Result
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Missing Total
Grade 0 9 (15) 20 (33) 18 (30) 8 (13) 0 0 55 (90)
Grade 1 0 0 0 0 0 0 0
Grade 2 0 0 1 (2) 0 0 0 1 (2)
Grade 3 0 0 0 0 0 0 0
Grade 4 0 0 0 0 0 0 0
Missing 4 (7) 1 (2) 0 0 0 0 5 (8)
Values are number of cases with percents in parentheses.
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regimen for melphalan. Melphalan is commonly adminis-
tered as 200 mg/m2 on a single day and less commonly as
100 mg/ m2 daily on 2 consecutive days as was done in the
propylene glycol-free melphalan HCl study. Prior prospective
studies in MM have used the 100 mg/m2 2-day dosing, and
authorities in the ﬁeld consider both methods of melphalan
administration to be equivalent [21,22]. A comparative study
did demonstrate a higher risk of mucositis with the 2-day
dosing scheme [26].
All patients in the phase IIb study (n ¼ 61) described here
demonstrated myeloma responses, with an ORR of 95% and a
CR rate of 31%. The ORR, based on the blinded, independent
review, was 100% with an overall CR rate of 21%. The lower
incidence of CRs based on the independent review compared
with the site review was attributed to missing data, such as
24-hour urine samples from select patients, that did not
allow for conﬁrmation of a CR and subsequent response
downgrading. In addition, patients in this study who had
relapsed from a prior ASCT (n ¼ 5) were shown to achieve a
response to salvage ASCT with EVOMELA.
Notably, nonhematologic TEAEs in this study were mostly
grade 1 or 2 in severity, and no treatment-related deaths
occurred despite enrollment of patients undergoing salvage
ASCT (8%) and patients aged 65 or above (30%). The TRM rate
reported in recently published studies using comparable i.v.
melphalan treatment regimens (200 mg/m2) and a similar
TRM deﬁnition, generally 3% [23-25].
Gastrointestinal TEAEs, in particular diarrhea, nausea,
and vomiting, occurred in >50% of patients in this study and
are expected adverse events associated with high-dose
melphalan; the rates of these adverse events were consis-
tent with the rates in recently published studies [23-25]. The
incidence of WHO grade 3 oral mucositis (which was spe-
ciﬁcally graded daily by the investigators) was only 13% in
the current study, after administration of EVOMELA, with no
grade 4 events compared with WHO grade 3 or 4 oral
mucositis incidences in the published literature after con-
ventional i.v. melphalan formulations of 46% [27]. The WHO
scale for rating mucositis is generally considered a more
speciﬁc and sensitive measure of mucositis than from gen-
eral adverse event reporting. The incidence of grade 3 or 4
mucositis, reported as adverse events of mucosal inﬂam-
mation and stomatitis using the NCI CTCAE scale, was also
lower in this study (15%) than rates generally reported in the
published literature with conventional i.v. melphalan (12% to
43%) [28,29]. However, it should be noted that these studies
were done with varying mucositis prophylaxis regimens,
limiting comparisons.
The currently approved i.v. melphalan formulations,
including Alkeran, contain propylene glycol, which has been
associated with signiﬁcant toxicities, especially when given
at high doses or with prolonged exposures [30]. Althoughpropylene glycol toxicities are usually reversible after
cessation of the offending agent, they may in some cases
require hemodialysis or be potentially life-threatening if not
aggressively treated [12]. The concentration of propylene
glycol in Alkeran for Injection (melphalan HCl) is greater
than 6 g/50 mg Alkeran. Thus, high-dose (200 mg/m2) con-
ditioning treatment of patients with MM undergoing ASCT
with Alkeran exposes patients to 24 g/m2 of propylene glycol.
When infused over 15 minutes, these patients are exposed to
a propylene glycol infusion rate that is nearly 60 times faster
than the recommended rate, which increases the potential
for propylene glycoleassociated adverse events. However,
clinically signiﬁcant propylene glycolerelated adverse
events are not generally identiﬁed in the ASCT setting.
In conclusion, this study conﬁrmed the efﬁcacy and safety
proﬁle of EVOMELA at a 200 mg/m2 dose in patients un-
dergoing upfront or salvage ASCT for MM and including pa-
tients up to 73 years of age [31]. Overall, EVOMELA was
shown to be effective, inducingMM responses for all patients
after successful myeloablation and subsequent engraftment
(neutrophil and platelet) with no TRM. The safety proﬁle of
EVOMELA in this study was shown to be consistent with the
established side effect proﬁle of high-dose i.v. melphalan,
with lower rates of grade 3 and 4 mucositis (WHO grade) or
mucositis/stomatitis (NCI CTCAE grade) than has been re-
ported in the recent literature after high-dose regimens with
conventional i.v. melphalan formulations.
Use of the Captisol technology has enabled the develop-
ment of propylene glycol-free melphalan HCl, which has
been shown to be amore stable formulation of i.v. melphalan
that does not require the propylene glycol diluent required
in current i.v. melphalan formulations, including Alkeran;
this new Captisol-enabled melphalan formulation is bio-
equivalent to Alkeran. The longer stability of EVOMELA
eliminates the time constraints imposed on pharmacists
and nursing staff when preparing and administering high-
dose melphalan infusions, allowing for the administration
of high-dose melphalan infusions for up to 8 hours after
reconstitution and resulting in more reliable delivery of
the planned high-dose melphalan conditioning regimen. By
eliminating the propylene glycol diluent required in current
melphalan formulations, EVOMELA HCl has the potential to
provide a safer method of administering the high-dose
melphalan conditioning regimens used in MM patients
undergoing ASCT and improves the clinical administration
logistics. These ﬁndings make EVOMELA an attractive alter-
native treatment option compared with other available i.v.
melphalan formulations for use in high-dose melphalan
therapy.
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